E-LIB Suche - Ergebnisse für: Lamanna, N.

1

MURANO: Final 7 year follow up and retreatment analysis in ..:

Kater, A. P. ; Harrup, R. ; Kipps, T. J....
Hematological Oncology. 41 (2023) S2 - p. 239-242 , 2023

Link: https://doi.org/10.1002/..

2

Zanubrutinib versus ibrutinib in relapsed/refractory chroni..:

Eichhorst, B. ; Lamanna, N. ; O'Brien, S. M....
Hematological Oncology. 41 (2023) S2 - p. 463-464 , 2023

Link: https://doi.org/10.1002/..

3

Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cel..:

Lee, H. ; Choi, M. ; Siddiqi, T....
Hematological Oncology. 41 (2023) S2 - p. 587-589 , 2023

Link: https://doi.org/10.1002/..

4

COMPARISON OF BLEEDING‐RELATED EVENTS IN PATIENTS WHO RECEI..:

Jurczak, W. ; Lamanna, N. ; Tam, C. S....
Hematological Oncology. 41 (2023) S2 - p. 758-759 , 2023

Link: https://doi.org/10.1002/..

5

COMPARISON OF BLEEDING-RELATED EVENTS IN PATIENTS WHO RECEI..:

Lamanna, N ; Tam, CS ; Jurczak, W...
Hematology, Transfusion and Cell Therapy. 45 (2023) - p. S161 , 2023

Link: https://doi.org/10.1016/..

6

Zanubrutinib safety/tolerability profile and comparison wit..:

Brown, J. R. ; Eichorst, B. ; Ghia, P....
Hematological Oncology. 41 (2023) S2 - p. 459-461 , 2023

Link: https://doi.org/10.1002/..

7

P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REV..:

Eyre, T. A. ; Wang, M. L. ; Shah, N. N....
HemaSphere. 6 (2022) - p. 991-992 , 2022

Link: https://doi.org/10.1097/..

8

P663: HEALTH-RELATED QUALITY OF LIFE OUTCOMES ASSOCIATED WI..:

Hillmen, P. ; Brown, J. ; Lamanna, N....
HemaSphere. 6 (2022) - p. 561-562 , 2022

Link: https://doi.org/10.1097/..

9

P671: TREATMENT SEQUENCES AND OUTCOMES OF PATIENTS WITH CLL..:

Mato, A. R. ; Manzoor, B. S. ; Coombs, C. C....
HemaSphere. 6 (2022) - p. 569-570 , 2022

Link: https://doi.org/10.1097/..

10

S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVE..:

Mato, A. R. ; Pagel, J. M. ; Coombs, C. C....
HemaSphere. 6 (2022) - p. 48-49 , 2022

Link: https://doi.org/10.1097/..

11

Spin-orbit coupling controlled ground states in the double ..:

Aczel, A. A. ; Chen, Q. ; Clancy, J. P....
Physical Review Materials. 6 (2022) 9 - p. , 2022

Link: https://doi.org/10.1103/..

12

PIRTOBRUTINIB (LOXO‐305), A NEXT GENERATION HIGHLY SELECTIV..:

Jurczak, W. ; Shah, N. N. ; Lamanna, N....
Hematological Oncology. 39 (2021) S2 - p. , 2021

Link: https://doi.org/10.1002/..

13

EFFECT OF DOSE MODIFICATIONS ON RESPONSE TO DUVELISIB IN PA..:

Ghia, P. ; Flinn, I.W. ; Lamanna, N....
Hematological Oncology. 37 (2019) S2 - p. 214-216 , 2019

Link: https://doi.org/10.1002/..

14

A PHASE 2 STUDY TO ASSESS THE SAFETY AND EFFICACY OF UMBRAL..:

Mato, A.R. ; Schuster, S.J. ; Lamanna, N....
Hematological Oncology. 37 (2019) S2 - p. 88-89 , 2019

Link: https://doi.org/10.1002/..

15

Second interim analysis of a phase 3 study evaluating idela..:

Ghia, P. ; Coutre, S.E. ; Furman, R.R....
Journal of Geriatric Oncology. 5 (2014) - p. S45-S46 , 2014

Link: https://doi.org/10.1016/..